Skip to main content
Explore URMC

menu

Lung Cancer (NSCLC): A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors

Research Question:
How safe is and what is the anti-cancer effectiveness of the investigational study drug, PF-06801591?

Basic Study Information

Purpose:
There are 2 parts to this study: dose escalation (Part 1) and dose expansion (Part 2). For Part 1, different doses and types of administration of PF-06801591 were tested and the information gathered was used to determine the optimal dosing regimen for further evaluation in Part 2. This study is currently open to Part 2; you will receive the investigational drug, PF06801591 every 28 days.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02573259?term=B8011001&rank=1
Study Reference #: ILUN17111

Lead Researcher (Principal Investigator)

Lead Researcher: Megan Baumgart

Study Contact Information

Study Coordinator: Amy Jasek
Phone: (585) 273-1912
Email: Amy_Jasek@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Carcinoma, Non-Small-Cell Lung

More information about Lung Cancer

Return to Search